Vanda Pharma announced initiation of FDA approved clinical study of Tradipitant patients with severe COVID-19 pneumonia
On Apr. 2, 2020, Vanda Pharmaceuticals announced initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The novel SARS-CoV-2 coronavirus is associated with a lower respiratory tract inflammation that often progresses to Acute Respiratory Distress Syndrome requiring mechanical ventilation.
Vanda Pharmaceuticals Inc. (“Vanda”) (Nasdaq: VNDA) today announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The novel SARS-CoV-2 coronavirus is associated with a lower respiratory tract inflammation that often progresses to Acute Respiratory Distress Syndrome (“ARDS”) requiring mechanical ventilation.
Tags:
Source: Vanda Pharmaceuticals Inc.
Credit:
